Adverum Biotechnologies to Present at Upcoming Conferences
November 15 2017 - 4:01PM
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy
company targeting unmet medical needs in serious rare and ocular
diseases, announced today that company executives will present at
upcoming conferences in November.
Event: |
|
The 29th Annual Piper
Jaffray Healthcare Conference |
Date: |
|
November 28, 2017 |
Time: |
|
12:10 – 12:30 p.m.
ET |
Location: |
|
New York, NY |
Presentation: |
|
Amber Salzman, Ph.D.,
president and chief executive officer |
|
|
|
Event: |
|
Barclays Gene Editing
& Gene Therapy Summit |
Date: |
|
November 30, 2017 |
Time: |
|
9:00 – 9:20 a.m.
ET |
Location: |
|
New York, NY |
Presentation: |
|
Amber Salzman, Ph.D.,
president and chief executive officer |
|
|
|
A live and replay audio webcast of the Piper Jaffray Healthcare
Conference presentation will be available from Adverum’s website at
http://investors.adverum.com.
About Adverum Biotechnologies, Inc.Adverum is a
leading gene therapy company targeting unmet medical needs in
serious rare and ocular diseases. Adverum has a robust pipeline
that includes product candidates designed to treat rare diseases
alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema
(HAE) as well as wet age-related macular degeneration (wAMD).
Leveraging a next-generation adeno-associated virus (AAV)-based
directed evolution platform, Adverum generates product candidates
designed to provide durable efficacy by inducing sustained
expression of a therapeutic protein. Adverum has collaboration
agreements with Regeneron Pharmaceuticals to research, develop, and
commercialize gene therapy products for ophthalmic diseases and
Editas Medicine to explore the delivery of genome editing medicines
for the treatment of inherited retinal diseases. Adverum’s core
capabilities include clinical development and in-house
manufacturing expertise, specifically in process development and
assay development. For more information please visit
www.adverum.com.
Adverum Contact:
Leone Patterson
Chief Financial Officer
650-665-7222
lpatterson@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024